Checkpoint Kinase 2 Inhibition Can Reverse Tamoxifen Resistance in ER-Positive Breast Cancer

• Published in: International journal of molecular sciences Vol. 23; no. 20; p. 12290
• Main Authors: Tsoi, Ho, Tsang, Wai-Chung, Man, Ellen P. S., Leung, Man-Hong, You, Chan-Ping, Chan, Sum-Yin, Chan, Wing-Lok, Khoo, Ui-Soon
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 14.10.2022; MDPI
• Subjects: Apoptosis; Ataxia; Breast cancer; DNA damage; Kinases; Mortality

Breast cancer is a heterogeneous disease. Tamoxifen is frequently used to treat ER-positive breast cancer. Our team has identified a novel splice variant of NCOR2, BQ323636.1 (BQ), that mediates tamoxifen resistance. However, the upstream factors that modulate BQ expression are not apparent. This st...